Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 5, 2015, Pages 617-632

  Popovics, Petra ^a,b,c   Frigo, Daniel E ^d,e   Schally, Andrew V ^a,b   Rick, Ferenc G ^a,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d University of Houston   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

5 AMP activated protein kinase; Calcium calmodulin dependent protein kinase kinase 2; Cancer metabolism; Prostate cancer

Indexed keywords

ADENOSINE PHOSPHATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DOCETAXEL; METFORMIN; NATURAL PRODUCT; PHENFORMIN; PROTEIN KINASE; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; SIMVASTATIN; ANDROGEN; ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CAMKK2 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ADAPTATION; AUTOPHAGY; CANCER CELL; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG TARGETING; ENERGY; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; METABOLISM; MIGRATION; MODULATION; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; REVIEW; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; MALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; DRUG DESIGN; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84928502222     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1005603     Document Type: Review

References (156)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
2. Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormonedependent prostate cancer. Onco Targets Ther 2013;6:391-402
3. Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother 2013;14:2237-47
4. El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013;5:25-40
5. Warburg O. The metabolism of carcinoma cells. J Cancer Res 1925;9:148-63
6. Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976;87:115-26
7. Potter VR. The biochemical approach to the cancer problem. Fed Proc 1958;17:691-7
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20
10. Parlo RA, Coleman PS. Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J Biol Chem 1984;259:9997-10003
11. Parlo RA, Coleman PS. Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 1986;886:169-76
12. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979;254:2669-76
13. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem 1997;272:28875-81
14. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-96
15. Franz MC, Anderle P, Burzle M, et al. Zinc transporters in prostate cancer. Mol Aspects Med 2013;34:735-41
16. Cortesi M, Fridman E, Volkov A, et al. New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer. Prostate 2010;70:1701-8
17. Dakubo GD, Parr RL, Costello LC, et al. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59:10-16
18. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005;5:143-53
19. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-5
20. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-55
21. Pillarsetty N, Punzalan B, Larson SM. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med 2009;50:1709-14
22. Yu EY, Muzi M, Hackenbracht JA, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011;36:192-8
23. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62
24. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011;13:1016-23
25. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76
26. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007;26:7825-32
27. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21
28. McInnes KJ, Brown KA, Hunger NI, Simpson ER. Regulation of LKB1 expression by sex hormones in adipocytes. Int J Obes (Lond) 2012;36:982-5
29. Frigo DE, Howe MK, Wittmann BM, et al. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgendependent migration of prostate cancer cells. Cancer Res 2011;71:528-37
30. Pearson HB, McCarthy A, Collins CM, et al. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 2008;68:2223-32
31. Mehenni H, Lin-Marq N, Buchet-Poyau K, et al. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 2005;14:2209-19
32. Song P, Wu Y, Xu J, et al. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation 2007;116:1585-95
33. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000
34. Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 2009;28:677-85
35. Xie M, Zhang D, Dyck JR, et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA 2006;103:17378-83
36. Konishi N, Nakamura M, Kishi M, et al. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 2003;94:764-8
37. Liu W, Chang BL, Cramer S, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007;13:5028-33
38. Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12- 22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol 2013;26:975-83
39. Tennakoon JB, Shi Y, Han JJ, et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alphamediated metabolic switch. Oncogene 2014;33(45):5251-61
40. Park HU, Suy S, Danner M, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009;8:733-41
41. Wu M, Shi L, Cimic A, et al. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res 2012;72:2833-43
42. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2:9-19
43. Woods A, Dickerson K, Heath R, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005;2:21-33
44. Hurley RL, Anderson KA, Franzone JM, et al. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005;280:29060-6
45. Massie CE, Lynch A, Ramos-Montoya A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33
46. Karacosta LG, Foster BA, Azabdaftari G, et al. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem 2012;287:24832-43
47. Sharma NL, Massie CE, Ramos-Montoya A, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013;23:35-47
48. Fu H, He HC, Han ZD, et al. MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer. Tumour Biol 2014. [Epub ahead of print]
49. Oakhill JS, Chen ZP, Scott JW, et al. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci USA 2010;107:19237-41
50. Mitchelhill KI, Michell BJ, House CM, et al. Posttranslational modifications of the 5'-AMP-activated protein kinase beta1 subunit. J Biol Chem 1997;272:24475-9
51. Scott JW, Ling N, Issa SM, et al. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem Biol 2014;21:619-27
52. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-93
53. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-24
54. Leprivier G, Remke M, Rotblat B, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013;153:1064-79
55. Bando H, Atsumi T, Nishio T, et al. Phosphorylation of the 6-phosphofructo- 2-kinase/fructose 2,6-bisphosphatase/ PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005;11:5784-92
56. Marsin AS, Bouzin C, Bertrand L, Hue L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2- kinase. J Biol Chem 2002;277:30778-83
57. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000;10:1247-55
58. Moon JS, Jin WJ, Kwak JH, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6- phosphofructo-2-kinase/fructose-2,6- bisphosphatase 2 in prostate cancer cells. Biochem J 2011;433:225-33
59. Mendoza EE, Pocceschi MG, Kong X, et al. Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH. Transl Oncol 2012;5:208-16
60. Eguchi S, Oshiro N, Miyamoto T, et al. AMP-activated protein kinase phosphorylates glutamine : fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells 2009;14:179-89
61. Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab 2008;295:E29-37
62. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005;280:9963-72
63. Wu N, Zheng B, Shaywitz A, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 2013;49:1167-75
64. Barnes K, Ingram JC, Porras OH, et al. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 2002;115:2433-42
65. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002;30:1064-70
66. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30
67. Beg ZH, Allmann DW, Gibson DM. Modulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem Biophys Res Commun 1973;54:1362-9
68. Carlson CA, Kim KH. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem 1973;248:378-80
69. Leclerc I, Lenzner C, Gourdon L, et al. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 2001;50:1515-21
70. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012;485:661-5
71. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65
72. Heemers HV, Verhoeven G, Swinnen JV. Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 2006;20:2265-77
73. Stoss O, Werther M, Zielinski D, et al. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2008;11:166-72
74. Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget 2013;4:1309-16
75. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007;104:12017-22
76. Bhalla K, Hwang BJ, Dewi RE, et al. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 2011;71:6888-98
77. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009;458:1056-60
78. Bungard D, Fuerth BJ, Zeng PY, et al. Signaling kinase AMPK activates stresspromoted transcription via histone H2B phosphorylation. Science 2010;329:1201-5
79. Zaugg K, Yao Y, Reilly PT, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011;25:1041-51
80. Liu Y, Borchert GL, Surazynski A, Phang JM. Proline oxidase, a p53- induced gene, targets COX-2/ PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 2008;27:6729-37
81. Liu Y, Borchert GL, Donald SP, et al. Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res 2009;69:6414-22
82. Pandhare J, Donald SP, Cooper SK, Phang JM. Regulation and function of proline oxidase under nutrient stress. J Cell Biochem 2009;107:759-68
83. Tsouko E, Khan AS, White MA, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 2014;3:e103
84. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22
85. White E. Deconvoluting the contextdependent role for autophagy in cancer. Nat Rev Cancer 2012;12:401-10
86. Nguyen HG, Yang JC, Kung HJ, et al. Targeting autophagy overcomes Enzalutamide resistance in castrationresistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 2014;33:4521-30
87. Chhipa RR, Wu Y, Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal 2011;23:1466-72
88. Bennett HL, Fleming JT, O'Prey J, et al. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis 2010;1:e72
89. Shi Y, Han JJ, Tennakoon JB, et al. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol 2013;27:280-95
90. Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/ 2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2-11
91. Kim J, Kim YC, Fang C, et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 2013;152:290-303
92. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90.
93. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26
94. Tzatsos A, Tsichlis PN. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 2007;282:18069-82
95. Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and posttranscriptional increases in cyclin D proteins. Cancer Res 2006;66:7783-92
96. Munkley J, Rajan P, Lafferty NP, et al. A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget 2014;5:131-9.
97. Nakano A, Kato H, Watanabe T, et al. AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol 2010;12:583-90
98. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle 2009;8:2385-98
99. Banko MR, Allen JJ, Schaffer BE, et al. Chemical genetic screen for AMPKalpha2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 2011;44:878-92
100. Thaiparambil JT, Eggers CM, Marcus AI. AMPK regulates mitotic spindle orientation through phosphorylation of myosin regulatory light chain. Mol Cell Biol 2012;32:3203-17
101. Miyamoto T, Oshiro N, Yoshino K, et al. AMP-activated protein kinase phosphorylates Golgi-specific brefeldin A resistance factor 1 at Thr1337 to induce disassembly of Golgi apparatus. J Biol Chem 2008;283:4430-8
102. Rios M, Foretz M, Viollet B, et al. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 2013;73:2628-38
103. Shen CH, Yuan P, Perez-Lorenzo R, et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 2013;52:161-72
104. Yang W, Hong YH, Shen XQ, et al. Regulation of transcription by AMPactivated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 2001;276:38341-4
105. Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG. Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget 2014;5:3785-99
106. Greer EL, Oskoui PR, Banko MR, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007;282:30107-19
107. Cornforth AN, Davis JS, Khanifar E, et al. FOXO3a mediates the androgendependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 2008;27:4422-33
108. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437:1109-11
109. Thomson DM, Herway ST, Fillmore N, et al. AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J Appl Physiol 2008;104:429-38
110. Kim I, He YY. Targeting the AMPActivated Protein Kinase for Cancer Prevention and Therapy. Front Oncol 2013;3:175
111. Xiang X, Saha AK, Wen R, et al. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-7
112. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558-65
113. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991;40:1259-66
114. Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62:2164-72
115. Vincent EE, Coelho PP, Blagih J, et al. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene 2014. [Epub ahead of print]
116. Zadra G, Photopoulos C, Tyekucheva S, et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014;6:1357
117. Fendt SM, Bell EL, Keibler MA, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013;73:4429-38
118. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8
119. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-6
120. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5
121. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69
122. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014;2:12
123. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86
124. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011;71:4366-72
125. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11:554-65
126. Spratt DE, Zhang C, Zumsteg ZS, et al. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16
127. Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013;31:3069-75
128. Zanders MM, Vissers PA, van de Poll-Franse LV. Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication? J Clin Oncol 2014;32:701
129. Bensimon L, Yin H, Suissa S, et al. the use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev 2014;23(10):2111-18
130. Azoulay L, Dell'Aniello S, Gagnon B, et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337-44
131. Wang SY, Chuang CS, Muo CH, et al. Metformin and the incidence of cancer in patients with diabetes: a nested casecontrol study. Diabetes Care 2013;36:e155-6
132. Margel D, Urbach D, Lipscombe LL, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013;105:1123-31
133. Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012;36:e243-50
134. Allott EH, Abern MR, Gerber L, et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 2013;16:391-7
135. Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 2013;31:3054-5
136. Chen D, Banerjee S, Cui QC, et al. Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One 2012;7:e47186
137. Vivar OI, Lin CL, Firestone GL, Bjeldanes LF. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol 2009;78:469-76
138. Watson GW, Beaver LM, Williams DE, et al. Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPS J 2013;15:951-61
139. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-22
140. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013;49:938-45
141. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6
142. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006;17:251-6
143. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675-90
144. Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008;29:2001-10
145. Klink JC, Tewari AK, Masko EM, et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 2013;73:754-62
146. Rana S, Blowers EC, Natarajan A. Small Molecule Adenosine 5'-Monophosphate Activated Protein Kinase (AMPK) Modulators and Human Diseases. J Med Chem 2014. [Epub ahead of print]
147. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor compound C is a potent AMPKindependent antiglioma agent. Mol Cancer Ther 2014;13:596-605
148. Tokumitsu H, Inuzuka H, Ishikawa Y, et al. STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem 2002;277:15813-18.
149. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 1998;334(Pt 1):177-87
150. Berglund L, Bjorling E, Oksvold P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 2008;7:2019-27
151. Laderoute KR, Amin K, Calaoagan JM, et al. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006;26:5336-47
152. Phoenix KN, Devarakonda CV, Fox MM, et al. AMPKalpha2 Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis. Genes Cancer 2012;3:51-62
153. Jung SN, Park IJ, Kim MJ, et al. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 2009;315:2433-41
154. Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal 2010;22:1554-61
155. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009;5:1403-13
156. McCullough LD, Tarabishy S, Liu L, et al. Inhibition of calcium/calmodulindependent protein kinase kinase beta and calcium/calmodulin-dependent protein kinase IV is detrimental in cerebral ischemia. Stroke 2013;44:2559-66